NASDAQ$AURA
Aura Biosciences Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and year ended December 31, 2023, and provided recent business highlights.
Aura Biosciences reported increased research and development expenses and general and administrative expenses for the fourth quarter of 2023, leading to a higher net loss compared to the same period in 2022. The company's cash and cash equivalents totaled $226.2 million as of December 31, 2023, sufficient to fund operations into the second half of 2026.
- Global Phase 3 CoMpass trial actively enrolling patients for small choroidal melanoma and indeterminate lesions.
- Received SPA agreement from FDA for the CoMpass trial design.
- Phase 2 data showed positive tumor control and visual acuity preservation rates with bel-sar.
- Phase 1 trial of bel-sar in bladder cancer is ongoing, with data expected in mid-2024.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$2.06M
Forward guidance
Aura Biosciences is focused on advancing bel-sar through clinical trials for choroidal melanoma and bladder cancer, with key milestones expected in the near term.
Tailwinds
- Advancing bel-sar in Phase 3 trial for choroidal melanoma.
- Positive Phase 2 data supports bel-sar's efficacy in ocular oncology.
- Expanding bel-sar into bladder cancer with ongoing Phase 1 trial.
- Strong cash position to fund operations into the second half of 2026.
- SPA agreement with FDA provides regulatory clarity for Phase 3 trial.
Headwinds
- Clinical trials are subject to uncertainties and may not yield desired results.
- Regulatory approvals are not guaranteed.
- Interim data may not be predictive of final results.
- Competition from existing and emerging therapies.
- Potential delays or setbacks in clinical development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q4 2023
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro